MedTrace Logo

Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

NCT02992223 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2016-12-14

No results posted yet for this study

Summary

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Conditions

  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Recurrent B-Cell Non-Hodgkin Lymphoma

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Principal Investigators

  • Barbara Botto, MD · A.O.U. Città della Salute e della Scienza

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992223 on ClinicalTrials.gov